GlassScriptPhysician profile
Aman Garsa
NPI 1821296047
$9,204.67
in general payments reported to CMS, 2019-2025
64 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,409 · 2020: $1,289 · 2021: $1,806 · 2022: $1,611 · 2023: $780 · 2024: $332 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,874 · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,873.87 |
| Education | $216.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $943.65 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $622.50 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $554.92 | 2019-2025 | Opdivo, Abecma |
| Pfizer INC. | $489.21 | 2019-2025 | |
| Amgen INC. | $416.66 | 2019-2023 | Kyprolis, Lumakras |
| Novartis Pharmaceuticals Corporation | $398.07 | 2019-2025 | |
| Daiichi Sankyo INC. | $327.91 | 2020-2025 | Enhertu |
| Janssen Biotech, INC. | $279.88 | 2019-2025 | Tecvayli, Rybrevant, Talvey |
| Pharmacyclics LLC, An Abbvie Company | $274.63 | 2019-2023 | Imbruvica |
| Genentech USA, INC. | $273.69 | 2019-2025 | Polivy, Venclexta, Lunsumio |
| Incyte Corporation | $261.06 | 2019-2025 | Monjuvi, Jakafi |
| Lilly USA, LLC | $247.35 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $241.43 | 2019-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Genzyme Corporation | $241.16 | 2019-2025 | |
| Seagen INC. | $223.35 | 2019-2023 | Tukysa, Adcetris |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Garsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.